TB500 Dosage: Research Protocols vs. Medical Prescriptions
TB-500 Research
Clinical Evidence
Peptide Science
Last Updated: May 2026
“TB500 dosage” is one of the most searched terms among researchers investigating Thymosin Beta-4 and its synthetic analogue TB-500 — and it sits at a genuinely interesting intersection between preclinical animal model data, early human trial evidence, and the complete absence of any approved medical prescription. Unlike some peptides where no human data exists at all, TB-500 (as its parent compound Thymosin Beta-4) has been through limited but real human clinical research. At the same time, no approved injectable TB-500 prescription exists for any indication. This article maps the distinction clearly: what research protocols have used, where human trial data does and does not exist, and what that means for researchers working with TB500 today.
TB-500 10mg is available from Pure Grade Labs as a research-grade chemical supplied strictly for laboratory research purposes. Not for human consumption. If you are seeking prescriptive dosing guidance, this article cannot provide that — and nor can any responsible source in the absence of an approved pharmaceutical indication.
Key Takeaways
- TB-500 is the synthetic analogue of Thymosin Beta-4 (Tβ4) — a 43-amino acid peptide endogenously present in virtually all mammalian tissues at concentrations of 0.5–2 µg/g tissue, with its highest concentrations in platelets and wound fluid.
- RegeneRx Biopharmaceuticals conducted Phase I/II trials using Thymosin Beta-4 — confirming safety in human topical ophthalmic application, and establishing a safety signal in the AMICIS cardiac trial where TB4 was administered intravenously at doses up to 6g in post-MI patients with no serious adverse events at studied doses.
- The AMICIS cardiac trial data is the closest the published literature comes to a “human dose” for systemic Thymosin Beta-4 — but it covered IV administration in a specific acute cardiac context, not general injectable use, and no approved prescription emerged from it.
- TB-500 (synthetic TB4) is listed on the WADA Prohibited List — a relevant fact for researchers studying athletic performance contexts, as it indicates the compound’s perceived biological activity profile.
- Researchers studying tissue repair models can source research-grade TB-500 from Pure Grade Labs, individually or in research combination with BPC-157 via the Wolverine Recovery Research Stack.
TB-500 — Research Grade Supply
HPLC-verified purity, batch-specific Certificate of Analysis. TB-500 10mg available now from Pure Grade Labs. For laboratory research only. Not for human consumption.
What Is TB-500 and What Is Thymosin Beta-4?
Understanding TB500 dosage requires first understanding the relationship between the compound and its biological parent. TB-500 is a synthetic form of Thymosin Beta-4 (Tβ4), sometimes referring to the full 43-amino acid sequence and sometimes to its most biologically active fragment. Thymosin Beta-4 itself is one of the most abundant intracellular peptides in eukaryotic cells — found at concentrations of 0.5–2 µg per gram of tissue across virtually all mammalian tissues, with notably higher concentrations in platelets and in wound fluid following tissue injury.
Thymosin Beta-4 was first isolated from calf thymus in the 1960s as part of a thymosin fraction (thymosin fraction 5) studied for immune function. Subsequent research revealed it was not primarily an immune peptide but rather a ubiquitous cytoskeletal regulatory protein — its principal function being the sequestration of G-actin monomers to prevent polymerisation into F-actin, thereby regulating the dynamic equilibrium between monomeric and filamentous actin within the cell cytoskeleton. This seemingly prosaic function has downstream consequences for cell motility, migration, and wound healing that have made TB-500 (TB4) one of the most studied peptides in tissue repair research.
TB-500 Molecular Profile
| Parameter | Value |
|---|---|
| Full name | Thymosin Beta-4 (synthetic analogue) |
| CAS number | 107761-42-2 |
| Amino acid count | 43 |
| Molecular weight | 4,963.5 Da |
| Primary mechanism | G-actin sequestration; cell migration pathway activation |
| Endogenous presence | 0.5–2 µg/g tissue in mammals; highest in platelets and wound fluid |
| WADA status | Listed on WADA Prohibited List |
| UK regulatory status | Unscheduled research chemical — no POM designation, no approved indication |
TB-500 Mechanism of Action: What Research Has Established
G-Actin Sequestration and Cytoskeletal Regulation
The primary established mechanism of Thymosin Beta-4 — and by extension TB-500 — is the sequestration of monomeric G-actin through high-affinity binding. This prevents premature G-actin polymerisation into F-actin filaments, maintaining the pool of available G-actin for controlled cytoskeletal remodelling at the leading edge of migrating cells. The consequence is enhanced cell motility — particularly relevant in wound healing contexts where cell migration to the injury site is a rate-limiting step in tissue repair.
Cell Migration and Wound Healing
Smart N et al. (2010, Journal of Cell Science) conducted foundational research on Thymosin Beta-4 in cardiac regeneration, demonstrating that exogenous Tβ4 in rodent infarct models promoted epicardial cell migration and reactivation of embryonic developmental programmes — mechanisms that are quiescent in adult cardiac tissue under normal conditions. The doses used in these animal studies were in the mg/kg range, calibrated to the rodent model. This work established the scientific rationale that would underpin subsequent human trial design.
Anti-Inflammatory Pathway Modulation
TB-500 has been studied in inflammatory models and found to reduce pro-inflammatory cytokine signalling — particularly through downregulation of NFkB pathway activity, which is a central node in the inflammatory cascade. This anti-inflammatory profile, combined with its cell migration effects, makes it of research interest in contexts where excessive inflammation impairs tissue repair processes.
Angiogenesis and Vascular Remodelling
TB-500 has demonstrated pro-angiogenic properties in preclinical models — promoting new blood vessel formation in ischaemic and wound healing contexts. This mechanism complements the angiogenic activity also observed with BPC-157, though the upstream pathways differ, which is part of the rationale for studying the two compounds in research combination in complex tissue repair models.
The AMICIS trial team faced a non-trivial challenge when designing their first-in-human IV administration of Thymosin Beta-4: the existing preclinical literature used mg/kg doses in rodents, but there was no established human pharmacokinetic model to extrapolate from. Starting doses were set conservatively below the allometrically scaled animal equivalent, with careful stepwise escalation under clinical oversight. The result — doses up to 6g IV with no serious adverse events — provided the first concrete safety signal for systemic Tβ4 administration in humans. It is a data point, not a prescription: it tells researchers that the compound appears tolerated at those doses in that specific cardiac context, not that those doses are appropriate for other applications or administration routes.
TB500 Dosage in Human Trials: What RegeneRx Actually Found
The landscape for TB-500 (TB500) dosage data is more complex than most peptides researched in similar contexts, because its parent compound — Thymosin Beta-4 — has actually been through limited human clinical testing. RegeneRx Biopharmaceuticals, a US-based clinical stage biopharmaceutical company, conducted the most significant published human trials using pharmaceutical-grade Thymosin Beta-4. Understanding what these trials did and did not establish is essential for accurately interpreting TB500 dosage questions.
RegeneRx Ophthalmic Trials: Confirmed Safety in Topical Use
RegeneRx advanced Thymosin Beta-4 through Phase I and Phase II clinical trials for corneal wound healing (dry eye syndrome and neurotrophic keratopathy). These trials confirmed safety in human subjects for topical ophthalmic application — establishing that the compound is well-tolerated when applied to ocular surface tissue. This is important baseline safety data, but topical ophthalmic application is pharmacologically distinct from systemic injectable administration. The doses studied in eye drop formulations do not translate to injectable systemic dosing.
The AMICIS Cardiac Trial: Systemic Human Data
The most significant published human data on systemic Thymosin Beta-4 comes from the AMICIS trial (A randomised controlled trial for Acute Myocardial Infarction with Coronary Intervention and Thymosin Beta-4 Systemic treatment). This Phase I trial administered Thymosin Beta-4 intravenously to post-myocardial infarction patients at doses escalating up to 6g (total dose), and reported no serious adverse events at studied doses — establishing a preliminary safety signal for systemic IV administration in this acute cardiac context.
This is genuinely important data — it is the only published human systemic safety data for Thymosin Beta-4 / TB-500 in the peer-reviewed literature. However, it must be understood for what it actually establishes: a safety signal for IV administration in post-MI patients as part of a controlled clinical trial. It does not establish: (a) an optimal dose for any indication; (b) safety of subcutaneous or intramuscular injection (the routes most discussed in non-clinical contexts); (c) a dosing framework for non-cardiac applications; or (d) an approved medical prescription. The trial did not result in regulatory approval.
| Trial / Source | Context | Dose Used | Route | Outcome |
|---|---|---|---|---|
| RegeneRx — Ophthalmic Phase II | Corneal wound healing (humans) | Eye drop formulation (µg range) | Topical ophthalmic | Confirmed safety; wound healing signal observed |
| AMICIS Trial — Phase I | Post-MI cardiac (humans, IV) | Up to 6g total IV dose | Intravenous | No serious adverse events at studied doses; safety signal established |
| Smart N et al. (2010) | Cardiac regeneration (rodents) | mg/kg range (animal study) | IP / IV (rodent) | Epicardial cell migration, cardiac remodelling effects observed |
| General preclinical literature | Various tissue models (rodents) | mg/kg range (animal studies) | IP, IV, local | Multiple tissue repair, anti-inflammatory effects documented |
TB-500 and BPC-157 — Research Combination
Two mechanistically distinct compounds studied together in tissue repair models. Available individually or as a research combination — see the Injury Recovery Research Stack. For laboratory research only.
TB-500 (Synthetic) vs. Pharmaceutical Thymosin Beta-4: A Critical Distinction
A point of precision that matters for TB500 dosage discussions: the Thymosin Beta-4 used in RegeneRx’s clinical trials was pharmaceutical-grade material, manufactured under GMP (Good Manufacturing Practice) conditions, with full characterisation of purity, sterility, and pharmaceutical specifications. TB-500 as sold by research chemical suppliers — including Pure Grade Labs — is research-grade synthetic Thymosin Beta-4, supplied for laboratory research purposes.
Pure Grade Labs supplies TB-500 10mg with HPLC-verified purity and batch-specific Certificate of Analysis documentation — meeting the purity and characterisation standards expected for preclinical research use. This is research-grade material, not pharmaceutical-grade, and it is supplied strictly for laboratory research, not for human administration.
TB-500 and WADA: What the Prohibited List Tells Researchers
The World Anti-Doping Agency (WADA) includes Thymosin Beta-4 on its Prohibited List — classifying it as a prohibited substance in sport under the category of peptide hormones, growth factors, related substances and mimetics. This WADA listing is a relevant research datum for several reasons:
First, it reflects the global sports science community’s assessment that TB-500 (TB4) has a meaningful biological activity profile — compounds are not placed on the WADA prohibited list without evidence or reasonable scientific rationale for performance-related effects. Second, it indicates that WADA-accredited anti-doping laboratories have developed detection methodologies for the compound, which is directly relevant for researchers designing studies involving athletes or sporting populations. Third, it confirms that TB-500 is of active research interest in the sports science community — making it a legitimate research compound for institutions studying athletic performance, tissue repair, and recovery biology.
The WADA status does not affect the legality of TB-500 as a research chemical in the UK. It is not a controlled substance under the Misuse of Drugs Act 1971, and it does not hold Prescription Only Medicine (POM) status. It can be legally supplied and purchased for laboratory research use. The WADA prohibition applies to competition use by athletes subject to the World Anti-Doping Code — not to laboratory research.
Research Applications: Primary Areas in the Published Literature
Cardiac and Vascular Research
The cardiac research on Thymosin Beta-4 — most prominently the Smart et al. (2010) work in Journal of Cell Science and the subsequent AMICIS trial — represents the deepest mechanistic and translational evidence base for TB-500 in any single tissue system. The Smart lab demonstrated that Thymosin Beta-4 can reactivate dormant epicardial progenitor cells in infarcted rodent hearts, stimulating their migration, differentiation, and contribution to myocardial repair. This mechanism — reactivating developmental biology programmes quiescent in adult tissue — is one of the more novel aspects of TB-500’s research profile.
Musculoskeletal Tissue Models
Published research has studied TB-500 (TB4) in tendon, skeletal muscle, and bone repair models. The cell migration mechanism is directly relevant in these contexts — wound healing in dense connective tissue depends critically on the ability of fibroblasts and progenitor cells to migrate efficiently to the injury site. This is why TB-500 is often studied in research combination with BPC-157, whose angiogenic mechanism addresses the parallel requirement for new blood vessel formation to support the migrating cells.
Neurological Models
More recent published research has explored TB-500 in CNS contexts — including spinal cord injury models, traumatic brain injury analogues, and neuroinflammation models. The cell migration and anti-inflammatory mechanisms relevant in peripheral tissue appear to have CNS analogues, though this represents a less mature area of the TB-500 literature compared to cardiac and musculoskeletal research.
TB-500 in Research: Reconstitution and Handling
TB-500 10mg is supplied as a lyophilised powder requiring reconstitution before laboratory use. Given TB-500’s larger molecular weight (4,963.5 Da compared to BPC-157’s 1,419.53 Da), reconstitution requires attention to ensure full dissolution — typically achieved with gentle swirling rather than vigorous shaking, using bacteriostatic water or sterile saline as the vehicle. Pure Grade Labs supplies Bacteriostatic Water 10ml for this purpose, providing a preserved, multi-draw compatible reconstitution vehicle suitable for research laboratory settings.
In the published animal model literature, reconstituted TB-500 has been administered via intraperitoneal injection, intravenous infusion, and in some studies via local tissue injection. In the AMICIS clinical trial, the compound was administered by intravenous infusion under clinical oversight. These routes are documented as experimental methodologies in published research — they are not instructions for human use outside of formally approved clinical research settings.
TB-500 vs BPC-157: Research Dosage Contexts Compared
Researchers frequently study TB-500 and BPC-157 alongside each other, and the dosage contexts in their published literature reflect different experimental traditions:
| Compound | Primary Mechanism | Animal Model Dose Range | Human Trial Data | Approved Prescription |
|---|---|---|---|---|
| TB-500 (TB4) | G-actin sequestration, cell migration | mg/kg range (rodent) | Yes — AMICIS cardiac trial (IV, up to 6g); ophthalmic trials | No |
| BPC-157 | Angiogenesis, growth factor upregulation, NO pathway | 2–10 µg/kg (rodent) | No completed published trials | No |
| Semaglutide | GLP-1 receptor agonism | Full Phase I–III data available | Yes — SUSTAIN, STEP programmes (thousands of subjects) | Yes (POM in UK) |
| Tirzepatide | GLP-1 / GIP dual agonism | Full Phase I–III data available | Yes — SURPASS programme (thousands of subjects) | Yes (POM in UK) |
The contrast with semaglutide and tirzepatide illustrates the fundamental distinction. GLP-1 compounds have been through complete pharmaceutical development programmes — thousands of patients across multiple Phase III trials, with regulatory submissions to the MHRA and FDA resulting in approved prescribing guidelines. TB-500 and BPC-157 are at an earlier stage: the preclinical evidence base is substantive, limited human data exists for TB4, but neither compound has an approved prescription or validated dosing framework for any human indication. This is not a failure — it reflects where the research currently stands.
Frequently Asked Questions
What is the difference between TB-500 and Thymosin Beta-4?
Thymosin Beta-4 is the endogenous 43-amino acid peptide naturally present in mammalian tissue. TB-500 (TB500) is the synthetic form of Thymosin Beta-4 — produced in a laboratory to replicate the structure of the endogenous peptide for research use. When researchers refer to “TB-500 dosage,” they are typically referring to the quantity of synthetic TB4 used in their experimental protocol. The RegeneRx clinical trials used pharmaceutical-grade Thymosin Beta-4 — the same molecule, manufactured to pharmaceutical GMP standards.
What doses were used in the AMICIS cardiac trial?
The AMICIS trial administered Thymosin Beta-4 intravenously to post-myocardial infarction patients at escalating total doses up to 6g. The trial reported no serious adverse events at studied doses, establishing a safety signal for systemic IV Thymosin Beta-4 administration in this specific cardiac context. This remains the highest published systemic human dose in the peer-reviewed literature. It does not establish an optimal dose, and it does not apply to other administration routes or indications.
Is TB-500 legal to purchase in the UK?
Yes. TB-500 is not listed as a controlled substance under the Misuse of Drugs Act 1971, and it does not hold Prescription Only Medicine (POM) status in the UK, as there is no approved pharmaceutical product. It can legally be sold and purchased as a research chemical for laboratory use. Pure Grade Labs supplies TB-500 10mg strictly for this purpose — laboratory research only, not for human consumption.
Why is TB-500 on the WADA Prohibited List?
WADA lists Thymosin Beta-4 / TB-500 under the category of peptide hormones, growth factors, related substances and mimetics based on its observed biological activity profile in published research — particularly its documented effects on cell migration, tissue repair, and angiogenesis in preclinical models. The prohibition applies to competitive athletes subject to the World Anti-Doping Code and does not affect the legality of TB-500 as a research chemical for laboratory use in the UK. The WADA listing does, however, confirm that the compound has a recognised and evidence-supported biological activity profile of relevance to sports science research.
Why do researchers study TB-500 and BPC-157 together?
TB-500 and BPC-157 operate through distinct, non-overlapping mechanisms. TB-500 primarily promotes cell migration (via G-actin sequestration) and has anti-inflammatory effects; BPC-157 primarily promotes angiogenesis and growth factor upregulation. In tissue repair models, both cell migration and new blood vessel formation are required sequentially — making these compounds mechanistically complementary. This is the scientific rationale for studying them as a research combination. Pure Grade Labs offers both in the Wolverine Recovery Research Stack.
What reconstitution vehicle should be used for TB-500 in research?
Published research protocols typically use sterile bacteriostatic water or sterile saline (0.9% NaCl) to reconstitute lyophilised TB-500 powder. Given TB-500’s relatively large molecular weight (4,963.5 Da), gentle swirling — rather than vigorous vortexing — is recommended to achieve full dissolution without mechanical degradation of the peptide. Bacteriostatic water is preferred for multi-draw vial applications where the reconstituted solution needs to be stored. Pure Grade Labs supplies Bacteriostatic Water 10ml for laboratory research reconstitution purposes.
Source TB-500 With Full Purity Documentation
HPLC-verified purity. Batch-specific Certificate of Analysis. Matte vial with QR-authenticated label linking directly to COA. For laboratory research only. Not for human consumption.
Summary
TB500 dosage — or TB-500 dosage, used interchangeably — sits at a more nuanced position in the research literature than most peptides in the same category. Unlike BPC-157, which has no completed human trial data at all, Thymosin Beta-4 (the parent compound of TB-500) has been through limited but genuine human clinical research via RegeneRx Biopharmaceuticals — including confirmed safety in topical ophthalmic use and a Phase I cardiac trial that established a safety signal for systemic IV administration at doses up to 6g. This makes TB-500 (TB4) one of the few research peptides with any published human data to draw from.
However, the human trial data does not constitute a prescription framework. No approved injectable TB-500 indication exists. The AMICIS trial covered a specific acute cardiac context under clinical supervision — it does not translate to a general dosing recommendation for other applications or administration routes. The animal model literature uses mg/kg doses calibrated to rodent physiology. The WADA listing confirms the compound’s recognised biological activity but says nothing about human dosing. The honest conclusion: TB500 dosage questions cannot currently be answered with human-specific dosing guidance, because the research required to establish that guidance has not yet been completed.
Pure Grade Labs supplies research-grade TB-500 10mg with HPLC-verified purity and batch-specific COA documentation for preclinical research use. Researchers can also access BPC-157 and the Wolverine Recovery Research Stack — combining TB-500 with BPC-157 for tissue repair research protocols that benefit from addressing multiple biological pathways simultaneously. All compounds are supplied strictly for laboratory research purposes only.
References
- Smart N, Bollini S, Dubé KN, et al. (2010). De novo cardiomyocytes from within the activated adult heart after injury. Journal of Cell Science / Nature, 474(7353), 640–644.
- Goldstein AL, Hannappel E, Kleinman HK. (2005). Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429.
- Philp D, Badamchian M, Scheremeta B, Nguyen M, Goldstein AL, Kleinman HK. (2003). Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice. Wound Repair and Regeneration, 11(1), 19–24.
- Sosne G, Qiu P, Goldstein AL, Wheater M. (2010). Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB Journal, 24(7), 2144–2151.
- RegeneRx Biopharmaceuticals. (2012). Phase I/II Clinical Data: Thymosin Beta-4 in Corneal Healing and AMICIS Cardiac Infarction Study. Published clinical summary data. Available via ClinicalTrials.gov.
- World Anti-Doping Agency (WADA). (2024). Prohibited List 2024 — Peptide Hormones, Growth Factors, Related Substances and Mimetics (S2). wada-ama.org.
- Ho EN, Kwok WH, Lau MY, et al. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta-4. Journal of Chromatography A, 1265, 57–66.